These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 10908011)

  • 1. Correlates of outpatient drug treatment drop-out among methamphetamine users.
    Maglione M; Chao B; Anglin MD
    J Psychoactive Drugs; 2000; 32(2):221-8. PubMed ID: 10908011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methamphetamine and cocaine users: differences in characteristics and treatment retention.
    Rawson R; Huber A; Brethen P; Obert J; Gulati V; Shoptaw S; Ling W
    J Psychoactive Drugs; 2000; 32(2):233-8. PubMed ID: 10908013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An emerging problem: methamphetamine abuse among treatment seeking youth.
    Gonzales R; Ang A; McCann MJ; Rawson RA
    Subst Abus; 2008; 29(2):71-80. PubMed ID: 19042326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of relapse after treatment for methamphetamine use.
    Brecht ML; von Mayrhauser C; Anglin MD
    J Psychoactive Drugs; 2000; 32(2):211-20. PubMed ID: 10908010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A descriptive analysis of participant characteristics and patterns of substance use in the CSAT methamphetamine treatment project: the first six months.
    Reiber C; Galloway G; Cohen J; Hsu JC; Lord RH
    J Psychoactive Drugs; 2000; 32(2):183-91. PubMed ID: 10908006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences between Ecstasy-using and nonusing methamphetamine users.
    Brecht ML; von Mayrhauser C
    J Psychoactive Drugs; 2002; 34(2):215-23. PubMed ID: 12691212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidemiology and public health Consequences of methamphetamine use in California's Central Valley.
    Gibson DR; Leamon MH; Flynn N
    J Psychoactive Drugs; 2002; 34(3):313-9. PubMed ID: 12422943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug court treatment for methamphetamine dependence: treatment response and posttreatment outcomes.
    Marinelli-Casey P; Gonzales R; Hillhouse M; Ang A; Zweben J; Cohen J; Hora PF; Rawson RA;
    J Subst Abuse Treat; 2008 Mar; 34(2):242-8. PubMed ID: 17596903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment response by primary drug of abuse: does methamphetamine make a difference?
    Luchansky B; Krupski A; Stark K
    J Subst Abuse Treat; 2007 Jan; 32(1):89-96. PubMed ID: 17175402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment outcomes for methamphetamine users receiving outpatient counselling from the Stimulant Treatment Program in Australia.
    McKetin R; Dunlop AJ; Holland RM; Sutherland RA; Baker AL; Salmon AM; Hudson SL
    Drug Alcohol Rev; 2013 Jan; 32(1):80-7. PubMed ID: 22642414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of injecting and noninjecting methamphetamine users.
    Domier CP; Simon SL; Rawson RA; Huber A; Ling W
    J Psychoactive Drugs; 2000; 32(2):229-32. PubMed ID: 10908012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C virus infection among methamphetamine-dependent individuals in outpatient treatment.
    Gonzales R; Marinelli-Casey P; Shoptaw S; Ang A; Rawson RA
    J Subst Abuse Treat; 2006 Sep; 31(2):195-202. PubMed ID: 16919748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Motivations for methamphetamine cessation among young people in northern Thailand.
    German D; Sherman SG; Sirirojn B; Thomson N; Aramrattana A; Celentano DD
    Addiction; 2006 Aug; 101(8):1143-52. PubMed ID: 16869844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mothers in substance abuse treatment: differences in characteristics based on involvement with child welfare services.
    Grella CE; Hser YI; Huang YC
    Child Abuse Negl; 2006 Jan; 30(1):55-73. PubMed ID: 16406024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pattern and related factors of cognitive impairment among chronic methamphetamine users.
    Wang TY; Fan TT; Bao YP; Li XD; Liang CM; Wang RJ; Ma J; Han Y; Meng SQ; Wu P; Shi J; Lu L
    Am J Addict; 2017 Mar; 26(2):145-151. PubMed ID: 28177556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The matrix model of outpatient stimulant abuse treatment: history and description.
    Obert JL; McCann MJ; Marinelli-Casey P; Weiner A; Minsky S; Brethen P; Rawson R
    J Psychoactive Drugs; 2000; 32(2):157-64. PubMed ID: 10908003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methamphetamine use and HIV risk among substance-abusing offenders in California.
    Farabee D; Prendergast M; Cartier J
    J Psychoactive Drugs; 2002; 34(3):295-300. PubMed ID: 12422940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of prize-based incentives on outcomes in stimulant abusers in outpatient psychosocial treatment programs: a national drug abuse treatment clinical trials network study.
    Petry NM; Peirce JM; Stitzer ML; Blaine J; Roll JM; Cohen A; Obert J; Killeen T; Saladin ME; Cowell M; Kirby KC; Sterling R; Royer-Malvestuto C; Hamilton J; Booth RE; Macdonald M; Liebert M; Rader L; Burns R; DiMaria J; Copersino M; Stabile PQ; Kolodner K; Li R
    Arch Gen Psychiatry; 2005 Oct; 62(10):1148-56. PubMed ID: 16203960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk and protective factors for nonmedical use of prescription stimulants and methamphetamine among adolescents.
    Herman-Stahl MA; Krebs CP; Kroutil LA; Heller DC
    J Adolesc Health; 2006 Sep; 39(3):374-80. PubMed ID: 16919799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk and protective factors for methamphetamine use and nonmedical use of prescription stimulants among young adults aged 18 to 25.
    Herman-Stahl MA; Krebs CP; Kroutil LA; Heller DC
    Addict Behav; 2007 May; 32(5):1003-15. PubMed ID: 16920275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.